medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2003, Number 3

<< Back Next >>

Alerg Asma Inmunol Pediatr 2003; 12 (3)

Immunomodulator mechanisms of the intravenous gammaglobulin (IVIG) in complement alterations

Méndez IJ, Huerta LJ, Bellanti JA

Language: Spanish
References: 41
Page: 75-81
PDF size: 103.82 Kb.


ABSTRACT

Complement has two major functions, protects against bacterial infections, inflammatory injury processes. The complement and humoral system work concomitantly in the physical elimination of pathogens and subsequent control of non specific inflammation. Alterations in various components of complement are known now to be associated with a wide variety of clinical presentations which manifests in recurrent infections, angioedema and autoimmune diseases. Several mechanisms of action of IVIG have been proposed. These include Fc receptor blockade, accelerated clearance of endogenous pathogenic autoantibodies, inhibition of components of the complement cascade, union and interference of the activation or stimulation of the inactivation of the complement factors avoiding the tissue injury. IVIG also inhibit and absorbs C3 and C4 in the cells and target tissues. IVIG has anti-inflammatory effects that prevent the generation of membrane attack cell complex, avoiding deposition of these fragments in the surface of the target cell and consequently tissue damage. The purpose of this article is to explain the IVIG possible mechanisms of action in complement deregulations, in order to understand the use of IVIG in diseases with complement alterations and be able to give another therapeutical option in diseases that can be fatal.


REFERENCES

  1. Bonilla FA, Geha RS. Primary immunodeficiency diseases. J Allergy Clin Immunol 2003; 111: 25-35.

  2. Walport MJ. Complement-first of two parts. New Engl J Med 2001; 344: 1058-1066.

  3. Walport MJ. Complement-second of two parts Mark J. Walport. New Engl J Med 2001; 344: 1140-1144.

  4. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271: 348-350.

  5. Soothill JF, Harvey BA. Defective opsonization: a common immunity deficiency. Arch Dis Child 1976; 51: 91-99.

  6. Soothill JF, Harvey BA. A defect of the alternative pathway of complement. Clin Exp Immunol 1977; 27: 30-33.

  7. Gerard C. Complement C5a in the sepsis syndrome-too much of a good thing? New Eng J Med 2003; 348: 167-169.

  8. Super M, Thiel S, Lu J, Levinsky RJ, Turner MW. Association of low levels of mannan-binding protein with a common defect of opsonization. Lancet 1989; 2: 1236-1239.

  9. Sumiya M, Super M, Tabona P et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991; 337: 1569-1570.

  10. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996; 17: 532-40.

  11. Stahi PD, Ezekowitz RA. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 1998; 10: 50-55.

  12. Madsen HO, Garred P, Thiel S et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013-3020.

  13. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from Southeast Africa and South America. J Immunol 1998; 161: 3169-3175.

  14. Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 2000; 165: 2637-2642.

  15. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital sedes. BMJ 1997; 314: 1229-1232.

  16. Lindahl G, Sjobring U, Johnsson E. Human complement regulators: a major target for pathogenic microorganisms. Curr Opin Immunol 2000; 12: 44-51.

  17. Noris M, Ruggenenti P, Pema A et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities: Italian Registry of familial and recurrent hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. J Am Soc Nephrol 1999; 10: 281-293.

  18. Wyatt RJ, Julian BA, Weinstein A, Rothfield NF, McLean RH. Partial H (beta 1H) deficiency and glomerulonephritis in two families. J Clin Immunol 1982; 2: 110-117.

  19. Thompson RA, Winterbom MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981; 46: 110-119.

  20. Warwicker P, Donne RL, Goodship JA et al. Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol Dial Transplant 1999; 14: 1229-1233.

  21. Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 1996; 3: 101-110.

  22. Boccuni P, Del Vecchio L, Di Noto R, Rotoli B. Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. Crit Rev Oncol Hematol 2000; 33: 25-43.

  23. Yamashina M, Ueda E, Kinoshita T et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323: 1184-1189.

  24. Merry AH, Rawlinson VI, Uchikawa M, Daha MR, Sim RB. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). Br J Haematol 1989; 73: 248-253.

  25. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: 1630-1634.

  26. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angioedema. Lancet 1998; 351: 1693-1697.

  27. Aulak KS, Pemberton PA, Rosen FS, Carrell RW, Lachmann PJ, Harrison RA. Dysfunctional C-1-Inhibitor(At), isolated from a type II hereditary-angioedema plasma, contains a P1 ‘reactive centre’ (Arg” border = 0 rc =’/math/rarr. Gif”His) mutation. Biochem J 1988; 253: 615-618.

  28. Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108: 470-479.

  29. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789-790.

  30. Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev 1998; 50: 59-87.

  31. Lories RJ, Blockmans D. Functional mechanisms of intravenous immunoglobulins. Acta Clin Belg 1998; 53(6): 360-6.

  32. Sacher RA. Intravenous immunoglobulin consensus statement. Journal of Allergy and Clinical Immunology 2001; 108: 52-66.

  33. Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342: 678-678.

  34. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, Szebeni J, Alving CR, Carroll MC, Berkower I, Stojilkovic SS, Metcalfe DD. (ab)’2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9(4): 431-8.

  35. Lutz HU, Stammler P, Jelezarova E, Nater M, Spath PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88: 184-93.

  36. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.

  37. Saadeh C, Bridges W, Burwick F. Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. South Med J 1995; 88: 866-870.

  38. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 729-35.

  39. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Arthritis Rheum 1995; 38(9): 1333-7.

  40. Miletic VD, Hester CG, Frank MM. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 1996; 15: 749-57.

  41. Ovilla-Martínez R, Méndez-Inocencio J, Bellanti JA. The use of IVIG in paroxysmal nocturnal hemoglobinuria (PNH). 2002 (presentado en el Primer Congreso de Inmunología y Alergia en Brasil en diciembre 2002).




2020     |     www.medigraphic.com